BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 30896825)

  • 1. The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging.
    Wang S; Niu X; Bao X; Wang Q; Zhang J; Lu S; Wang Y; Xu L; Wang M; Zhang J
    Oncol Rep; 2019 May; 41(5):2636-2646. PubMed ID: 30896825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Qilian Formula Inhibits Tumor Cell Growth in a Bone Metastasis Model of Lung Cancer.
    Wang Q; Zhao B; Li J; Zhao J; Wang C; Li Q; Yang W; Xu L; Gong Y
    Integr Cancer Ther; 2023; 22():15347354231217274. PubMed ID: 38130184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats.
    Netland IA; Førde HE; Sleire L; Leiss L; Rahman MA; Skeie BS; Miletic H; Enger PØ; Goplen D
    J Neurooncol; 2016 Aug; 129(1):57-66. PubMed ID: 27283525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.
    McGowan DR; Skwarski M; Bradley KM; Campo L; Fenwick JD; Gleeson FV; Green M; Horne A; Maughan TS; McCole MG; Mohammed S; Muschel RJ; Ng SM; Panakis N; Prevo R; Strauss VY; Stuart R; Tacconi EMC; Vallis KA; McKenna WG; Macpherson RE; Higgins GS
    Eur J Cancer; 2019 May; 113():87-95. PubMed ID: 30991262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib.
    Sahin I; Azab F; Mishima Y; Moschetta M; Tsang B; Glavey SV; Manier S; Zhang Y; Sacco A; Roccaro AM; Azab AK; Ghobrial IM
    Am J Hematol; 2014 Nov; 89(11):1030-6. PubMed ID: 25060991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.
    Vansteenkiste JF; Canon JL; De Braud F; Grossi F; De Pas T; Gray JE; Su WC; Felip E; Yoshioka H; Gridelli C; Dy GK; Thongprasert S; Reck M; Aimone P; Vidam GA; Roussou P; Wang YA; Di Tomaso E; Soria JC
    J Thorac Oncol; 2015 Sep; 10(9):1319-1327. PubMed ID: 26098748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
    Martin SK; Gan ZY; Fitter S; To LB; Zannettino AC
    Leuk Res; 2015 Mar; 39(3):380-7. PubMed ID: 25624048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTPRH promotes the progression of non-small cell lung cancer via glycolysis mediated by the PI3K/AKT/mTOR signaling pathway.
    Wang S; Cheng Z; Cui Y; Xu S; Luan Q; Jing S; Du B; Li X; Li Y
    J Transl Med; 2023 Nov; 21(1):819. PubMed ID: 37974250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas.
    Anderson JL; Park A; Akiyama R; Tap WD; Denny CT; Federman N
    PLoS One; 2015; 10(9):e0133610. PubMed ID: 26402468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin and buparlisib synergistically induce apoptosis of non-small lung cancer (NSCLC) cells via Akt/FoxO3a/Puma axis.
    Shanshan W; Hongying M; Jingjing F; Rui Y
    Toxicol In Vitro; 2024 May; 97():105801. PubMed ID: 38479708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcutaneous carbon dioxide application suppresses bone destruction caused by breast cancer metastasis.
    Takemori T; Kawamoto T; Ueha T; Toda M; Morishita M; Kamata E; Fukase N; Hara H; Fujiwara S; Niikura T; Kuroda R; Akisue T
    Oncol Rep; 2018 Oct; 40(4):2079-2087. PubMed ID: 30066936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
    Lee HY; Oh SH; Suh YA; Baek JH; Papadimitrakopoulou V; Huang S; Hong WK
    Clin Cancer Res; 2005 Aug; 11(16):6065-74. PubMed ID: 16115952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ImmunoPET Imaging of CD146 in Murine Models of Intrapulmonary Metastasis of Non-Small Cell Lung Cancer.
    England CG; Jiang D; Hernandez R; Sun H; Valdovinos HF; Ehlerding EB; Engle JW; Yang Y; Huang P; Cai W
    Mol Pharm; 2017 Oct; 14(10):3239-3247. PubMed ID: 28825843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells.
    Fujita H; Gomori A; Fujioka Y; Kataoka Y; Tanaka K; Hashimoto A; Suzuki T; Ito K; Haruma T; Yamamoto-Yokoi H; Harada N; Sakuragi M; Oda N; Matsuo K; Inada M; Yonekura K
    PLoS One; 2016; 11(10):e0164830. PubMed ID: 27736957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis.
    Hong SH; Kim YS; Lee JE; Kim IH; Kim SJ; Han D; Yoo IeR; Chung YG; Kim YH; Lee KY; Kang JH
    Cancer Res Treat; 2016 Jul; 48(3):1110-9. PubMed ID: 26790969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anticancer effects of Cucurbitacin I inhibited cell growth of human non‑small cell lung cancer through PI3K/AKT/p70S6K pathway.
    Zhu X; Huang H; Zhang J; Liu H; Ao R; Xiao M; Wu Y
    Mol Med Rep; 2018 Feb; 17(2):2750-2756. PubMed ID: 29207097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors.
    Wu YL; Zhang LI; Trandafir L; Dong T; Duval V; Hazell K; Xu B
    Anticancer Res; 2016 Nov; 36(11):6185-6194. PubMed ID: 27793950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of RUNX3 expression promotes cancer-associated bone destruction by regulating CCL5, CCL19 and CXCL11 in non-small cell lung cancer.
    Kim HJ; Park J; Lee SK; Kim KR; Park KK; Chung WY
    J Pathol; 2015 Dec; 237(4):520-31. PubMed ID: 26239696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
    Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
    J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.
    Inoue K; Karashima T; Fukata S; Nomura A; Kawada C; Kurabayashi A; Furihata M; Ohtsuki Y; Shuin T
    Clin Cancer Res; 2005 Sep; 11(18):6669-77. PubMed ID: 16166446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.